ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Isis Pharmaceuticals, Inc." (ISIS) Report Updated: Apr 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Isis Pharmaceuticals, Inc." (ISIS)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology
Competitors: ANAC, INSY, PRTA, BSTC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: C down downgrade
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Isis Pharmaceuticals, Inc."© quotemedia

Company Profile

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using antisense drug discovery platform. Its product pipeline comprises 26 drugs to primarily treat cardiovascular, metabolic, severe, and rare diseases, as well as cancer. The company’s flagship product, KYNAMRO, is an apo-B synthesis inhibitor in development for the reduction of low-density lipoprotein cholesterol. The company has collaboration agreements with Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy; Bristol-Myers Squibb to discover, develop, and commercialize antisense drugs targeting proprotein convertase subtilisin/kexin type 9; and Ortho-McNeil-Janssen Pharmaceuticals, Inc. to discover, develop, and commercialize antisense drugs to treat metabolic diseases, including type 2 diabetes. It also has a strategic relationship with Eli Lilly and Company for the development of LY2181308, an antisense inhibitor of survivin; and a strategic alliance with GlaxoSmithKline to develop new drugs against targets for rare and serious diseases. The company was founded in 1989 and is headquartered in Carlsbad, California.

Recent News: "Isis Pharmaceuticals, Inc."